All News
Filter News
Found 237 articles
-
Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County
7/7/2022
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., has been named for the 2nd year in a row as one of the Best Places to Work by the Orange County Business Journal.
-
Mindset Pharma was granted allowance by the U.S. Patent and Trademark Office for its application for a psilocybin-based family of drugs to treat central nervous system disorders.
-
Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders
7/6/2022
Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for Mindset’s patent application number 17/387,864, titled “3-Pyrrolidine-Indole Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”
-
AION Labs, In Continued Partnership with BioMed X, Launches Fourth Global Call for Application: Prediction of Clinical Trial Outcome in Cancer Patient Populations
6/29/2022
AION Labs, Israel -based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), seeks global research talent for new startup focused on: "Prediction of Clinical Trial Outcome in Biomarker-Stratified Cancer Patient Populations"
-
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
6/29/2022
Mindset Pharma Inc. today announced that the Company has developed a novel, patent-pending, intranasal platform formulation technology expected to deliver improved central system (CNS) penetration of first and subsequent generations of psychedelic medicines.
-
Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin
6/22/2022
Mindset Pharma Inc. today announced that the Company has entered into an innovative research collaboration with the Centre for Addiction and Mental Health (“CAMH”).
-
Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders
6/10/2022
Mindset Pharma Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Mindset’s patent application number 17/387,845.
-
Joydeep Goswami Appointed Interim CFO; Sam Samad to Depart Illumina
6/9/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced Joydeep Goswami, Chief Strategy and Corporate Development Officer, will also serve as interim Chief Financial Officer while the company conducts a search for a permanent CFO.
-
Willem Appelo to succeed Sophie Bechu as Philips’ Chief Operations Officer
6/7/2022
Royal Philips, a global leader in health technology, announced that Willem Appelo will join Philips’ Executive Committee, effective July 18, 2022, and succeed Sophie Bechu as Chief Operations Officer per October 1, 2022.
-
Mindset Pharma to Participate in Upcoming Conferences in June 2022
6/7/2022
Mindset Pharma Inc. today announced that management will participate in three upcoming conferences Grizzle Psychedelics Con 2022 to be held virtually on Wednesday, June 8, 2022.
-
EVERSANA and Limitless Minds Advance Pharmaceutical Sales Performance with New Cognitive & Behavioral Training Solution
6/2/2022
EVERSANA™ announced the launch of an integrated learning and performance solution for life sciences professionals.
-
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
5/12/2022
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") , a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it is making headway in progressing its Family 1 lead clinical candidate, MSP-1014, towards clinical trials.
-
Could big pharma buy out much of the biotech industry? Yes, according to analysts. But that’s not likely to happen anytime soon.
-
Univar Solutions Expands Pharmaceutical Products Portfolio Through New Distribution Agreement with Ashland
4/12/2022
Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), today expanded its specialty ingredient portfolio in Mexico and Brazil through a new distribution agreement with Ashland, a focused additives and specialty ingredients company.
-
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will face its first big test since Aduhelm as it weighs the merits of Amylyx's AMX0035 for ALS on Wednesday, March 30.
-
With all of this innovation coming down the pike, Gallant shared that Daiichi Sankyo is currently in growth mode, particularly when it comes to oncology.
-
Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014
1/25/2022
Mindset Pharma Inc. today announced that it has entered into a pharmaceutical manufacturing agreement with a leading contract development and manufacturing organization (CDMO) for the production of pharmaceutical grade batches of Mindset’s next-generation psilocybin drug candidate, MSP-1014.
-
Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer
1/19/2022
Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization, announced the appointment of Sauri Gudlavalleti as its Chief Operating Officer.
-
Syneos Health Appoints Two New Independent Directors
1/18/2022
Syneos Health ® today announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors.
-
It's been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.